Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, L.
Right arrow Articles by Yu, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, L.
Right arrow Articles by Yu, Y.
Clinical Cancer Research Vol. 9, 3660-3666, September 1, 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Loss of the Expression of the Tumor Suppressor Gene ARHI Is Associated with Progression of Breast Cancer1

Lin Wang2,, 3, Ashraful Hoque2, Robert Z. Luo, Jiuhong Yuan, Zhen Lu, Arata Nishimoto, Jinsong Liu, Aysegul A. Sahin, Scott M. Lippman, Robert C. Bast, Jr. and Yinhua Yu4

Departments of Experimental Therapeutics [L. W., R. Z. L., J. Y., Z. L., A. N., R. C. B., Y. Y.], Clinical Cancer Prevention [A. H., S. M. L.], and Pathology [J. L., A. A. S.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Purpose: Ductal carcinoma in situ (DCIS) is a preinvasive-stage breast carcinogenesis that accounts for ~20~25% of mammographically detected breast cancers. A significant fraction of untreated DCIS will evolve into invasive cancer. ras homologue I (ARHI) is an imprinted tumor suppressor gene that is expressed in normal breast epithelial cells but absent or down-regulated in breast cancer cells. This study investigated the relationship of ARHI expression to the progression of breast cancer.

Experimental Design: We analyzed ARHI expression in DCIS, invasive breast carcinoma, and adjacent normal breast epithelium from 64 formalin-fixed, paraffin-embedded DCIS specimens by both immunohistochemistry and in situ hybridization. We also analyzed the correlation between ARHI expression and progression of breast cancer, as well as the correlation of ARHI expression and cyclin D1 and p21WAF1/CIP1 expression in DCIS.

Results: Normal breast epithelium was found in all of the specimens and invasive breast carcinoma was found in 23 specimens. ARHI mRNA and protein were detected in all of the normal breast epithelia. ARHI expression was detected mainly in cytoplasm and rarely present in the nucleus. By histochemical analysis, ARHI expression was down-regulated in 41% (26 of 64) of DCIS and 70% (16 of 23) of invasive carcinomas comparing the specimens with adjacent normal breast epithelium. When DCIS and invasive cancer were present in the same sample, ARHI was further down-regulated in 26% (6 of 23) of invasive carcinoma. In four cases [4 (17%) of 23] of invasive carcinoma, ARHI protein expression was totally lost. Consistent results were obtained with an in situ hybridization assay for ARHI at the mRNA level. Higher levels of expression of cyclin D1 and p21WAF1/CIP1 were observed in DCIS than in the adjacent epithelia. The expression of cyclin D1 and p21WAF1/CIP1 was inversely correlated with that of ARHI.

Conclusions: Our results indicate that ARHI expression is markedly down-regulated in DCIS, and a further decrease in ARHI expression is associated with progression of breast cancer.




This article has been cited by other articles:


Home page
JCOHome page
J. P.A. Baak, P. J. van Diest, F. J. Voorhorst, E. van der Wall, L. V.A.M. Beex, J. B. Vermorken, and E. A.M. Janssen
Prospective Multicenter Validation of the Independent Prognostic Value of the Mitotic Activity Index in Lymph Node-Negative Breast Cancer Patients Younger Than 55 Years
J. Clin. Oncol., September 1, 2005; 23(25): 5993 - 6001.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Nishimoto, Y. Yu, Z. Lu, X. Mao, Z. Ren, S. S. Watowich, G. B. Mills, W. S-L. Liao, X. Chen, R. C. Bast Jr., et al.
A Ras Homologue Member I Directly Inhibits Signal Transducers and Activators of Transcription 3 Translocation and Activity in Human Breast and Ovarian Cancer Cells
Cancer Res., August 1, 2005; 65(15): 6701 - 6710.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
J. Colicelli
Human RAS Superfamily Proteins and Related GTPases
Sci. Signal., September 14, 2004; 2004(250): re13 - re13.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.